AMRI partners with biotech to aid drug discovery efforts at new Buffalo site

By Zachary Brennan

- Last updated on GMT

AMRI partners with biotech to aid drug discovery efforts at new Buffalo site

Related tags Pharmacology Drug design

Albany Molecular Research Inc. (AMRI) has signed a three-year collaborative agreement with biotechnology company HarkerBIO to co-market their drug discovery services to clients. 

As part of the agreement, AMRI gains access to HarkerBIO's high-resolution, structure-determination expertise and capabilities, while HarkerBIO's customers will be able to access and benefit from AMRI's global capabilities.

The collaboration comes as AMRI is building a new drug discovery site in Buffalo, NY, after closing a discovery and development plant​ last year in Syracuse, NY.

"Our new center in Buffalo offers customers leading-edge platforms and capabilities to translate early discoveries to the clinic via an integrated approach leveraging our expertise in chemistry, biology and pharmacology all located in a single site in the US​," said Michael Luther, SVP, Discovery and Development, AMRI.

Luther explained to that HarkerBIO expertise will be focused on determining “the near atomic-resolution, three-dimensional structures of drug target and drug target-therapeutic agent complexes, to accelerate the drug design process. HarkerBIO's technology directly images a drug's mechanism of action, which is critical to optimize a drug candidate and to capture a strong IP position​.”

The alliance with HarkerBIO is also aimed at accelerating decision making and success in the translation from discovery to the clinic. 

"We have a responsibility to our partners and customers to help drive the translation of innovation to the clinic to bridge the current gaps in discovery and development​," Luther said, "Our strategy is to leverage and build creative and effective collaborations with on-campus and off-campus partners from global Pharma to academia including technology partners within this unique public-private environment​."

Related news

Show more

Related products

show more

Saama accelerates data review processes

Saama accelerates data review processes

Content provided by Saama | 25-Mar-2024 | Infographic

In this new infographic, learn how Saama accelerates data review processes. Only Saama has AI/ML models trained for life sciences on over 300 million data...

More Data, More Insights, More Progress

More Data, More Insights, More Progress

Content provided by Saama | 04-Mar-2024 | Case Study

The sponsor’s clinical development team needed a flexible solution to quickly visualize patient and site data in a single location

Related suppliers

Follow us


View more